Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
Qian HuangFeifei LiuJianzhen ShenPublished in: Personalized medicine (2019)
Aim: In this study, four datasets concerning 167 diffuse large B-cell lymphoma (DLBCL) patients versus 56 controls and seven datasets involving 280 germinal center B-cell like (GCB) versus 224 activated B-cell like (ABC) DLBCL were included. Materials & methods: We identified 80 different expression genes (DEGs) for DLBCL versus nontumor and 77 DEGs for GCB versus ABC DLBCL. Results: These DEGs were found to be enriched in cell activity, signal transduction and extracellular region. Then ten central node genes for DLBCL versus nontumor and two hub genes for GCB versus ABC DLBCL were identified. Last, PAICS, IRF4 and PTPN1 were explored to be correlated with poor prognosis in DLBCL patients. Conclusion: Our study has identified critical genes from transcriptional profiles for DLBCL.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- poor prognosis
- genome wide
- end stage renal disease
- bioinformatics analysis
- newly diagnosed
- long non coding rna
- chronic kidney disease
- dna methylation
- peritoneal dialysis
- gene expression
- genome wide identification
- stem cells
- single cell
- dendritic cells
- binding protein
- cell therapy
- network analysis